TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21948942
Drug: Intravenous infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous infliximab
Study: 9813532
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg kg-1
Study: 31597621
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise training sessions three times per week with daily oral cholecalciferol supplementation
Study: 31359435
Drug: Individual/Group Supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual/Group Supportive Therapy (IGST)
Study: 24298766
Drug: Medication (loratadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (loratadine tablet and azelastine hydrochloride nasal spray)
Study: 18165210
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine ophthalmic solution 0.4%
Study: 12095313
Drug: VEGF-plasmid/liposome (VEGF-P/L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF-plasmid/liposome (VEGF-P/L) - 2000 microg of VEGF plasmid, 2000 microl of DOTMA:DOPE
Study: 7032640
Drug: Adriamycin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adriamycin (50 mg in 50 ml of saline for 30 min)
Study: 17966758
Drug: Chlorpropamide 250
Normalized name: chlorpropamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide 250 mg tablet (test formulation)
Study: 16321616
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg olmesartan medoxomil
Study: 16321616
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg olmesartan medoxomil
Study: 16321616
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lisinopril plus 20 mg olmesartan medoxomil
Study: 16321616
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg lisinopril plus 40 mg olmesartan medoxomil
Study: 11912111
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment during control period)
Study: 9797755
Drug: Inhaled LPS
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled LPS (60 micrograms)
Study: 30843501
Drug: 600 IU
Normalized name: Vitamin E 4600 IU/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 IU daily vitamin D3 supplementation
Study: 30843501
Drug: 1000 IU
Normalized name: D 1000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 IU daily vitamin D3 supplementation
Study: 30843501
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU daily vitamin D3 supplementation
Study: 29356445
Drug: Repeated exposure
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated exposure to weather-related stressors (30 min of a 3°C decrease in temperature, simulated rain, or 2 hr of food removal, 4 times daily for 3 weeks)
Study: 8846489
Drug: Mefloquine 25
Normalized name: mefloquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 25 mg/kg (M25)
Study: 8846489
Drug: Mefloquine 25
Normalized name: mefloquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 25 mg/kg (M25) split dose
Study: 2210983
Drug: Intralesional corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional corticosteroid injections combined with internal urethrotomy
Study: 434434
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (4 ml)
Study: 434434
Drug: Tetracaine 0.5%
Normalized name: TETRACAINE 0.5% VISCOUS (FORTE) OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 0.5% (4 ml)
Study: 26834462
Drug: Cariprazine (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine (3, 6, or 9 mg/day)
Study: 22882724
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg once-daily for 12 weeks
Study: 18365859
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) for 24 months
Study: 15997446
Drug: Laparoscopic rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic rectal surgery
Study: 8920706
Drug: Serotype G2
Normalized name: Rotavirus serotype G2 Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype G2 vaccine
Study: 27919453
Drug: Tartary buckwheat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tartary buckwheat (TB) intervention group (daily replacement of a portion of staple food with TB food)
Study: 17984375
Drug: Flavonoid-rich dark
Normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonoid-rich dark chocolate (40 g, 70% cocoa)
Study: 2973471
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic hormone (ANH) infusion (0.75 pmol/kg.min)
Study: 30307347
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of scenario-based and conventional training (Arm 3)
Study: 28162145
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy using a mobile application (CBT‐I‐MA)
Study: 19399934
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg parecoxib infusion 30 min before induction of anesthesia and at 12 h after the first dose
Study: 19399934
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion as placebo
Study: 17645463
Drug: 1-week furazolidone-based
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-week furazolidone-based quadruple therapy (FABO1)
Study: 17645463
Drug: 2-week furazolidone-based
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week furazolidone-based quadruple therapy (FABO2)
Study: 14679124
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg/day) concomitantly with EC chemotherapy (epirubicin 75 mg/m² + cyclophosphamide 600 mg/m² on day 1, every 21 days for four cycles)
Study: 7889884
Drug: High boron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High boron intake (approximately 3.25 mg boron/2000 kcal/day)
Study: 7889884
Drug: Low boron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low boron intake (approximately 0.25 mg boron/2000 kcal/day)
Study: 2986422
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms CRF dosage
Study: 26762123
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality exposure therapy (VRETp) combined with treatment as usual (TAU)
Study: 18685353
Drug: Serotonin and
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin and noradrenaline-reuptake inhibitors
Study: 27973619
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg/d
Study: 15886247
Drug: Metformin 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1500 mg/d
Study: 31769886
Drug: Metformin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (all doses)
Study: 16594932
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic acid gel (LVG)
Study: 12477508
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (estradiol, 2 mg/d, and norethisterone acetate, 1 mg/d)
Study: 2709206
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic therapy (Group I)
Study: 6103766
Drug: Synthetic LHRH
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic LHRH (HOE 471) administered intranasally for 4 weeks
Study: 12001541
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin
Study: 22828032
Drug: Bolus feeding
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus feeding (Group A) administered in 10 minutes followed by continuous feeding for 3 hours.
Study: 17164234
Drug: Prescribed medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed medications (average 3.7 prescribed medicines)
Study: 17164234
Drug: Determinants predicting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Determinants predicting polypharmacy: breathlessness, hypertension, dependency on instrumental activities of daily living, low subjective health, medication disagreement between doctors and patients
Study: 27881555
Drug: Dose-adjusted VKA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted VKA daily with DAPT stratification (group 3)
Study: 27881555
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg daily plus P2Y12 inhibitor for 12 months (group 1)
Study: 27881555
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily with DAPT stratification (group 2)
Study: 24188941
Drug: Honey-flavored corn
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey-flavored corn syrup as placebo
Study: 19282468
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m(2)/3 weeks)
Study: 17578320
Drug: nmAP (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nmAP (1.5 ml on Shenque acupoint once daily, placebo liquid 10 ml twice daily)
Study: 25125053
Drug: Ketorolac +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac + Acetazolamide (250 mg acetazolamide before anesthetic induction and 30 mg ketorolac in the immediate postoperative period)
Study: 25125053
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg in the immediate postoperative period)
Study: 19057629
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with 0.5% lidocaine 9 mL mixed with 1 mL of steroid
Study: 8741094
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ketoprofen lysine salt
Study: 2067317
Drug: Cyclandelate (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate (1200 mg, single oral dosage)
Study: 14572572
Drug: Prednisolone therapy
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone therapy
Study: 16214825
Drug: Azathioprine therapy
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine therapy
Study: 28232467
Drug: Internet-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioural writing therapy (IB-CBWT) for PTSD, guided by a therapist, comprising two written assignments per week over a 5-week period.
Study: 28232467
Drug: Wait-list (WL)
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Wait-list (WL) control group receiving treatment after a waiting period of 5 weeks.
Study: 28232467
Drug: Internet-based cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioural writing therapy (IB-CBWT) for PTSD.
Study: 25604313
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg (intensive)
Study: 8431125
Drug: Electrosurgical dissection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrosurgical dissection with 'L' hook and spatula electrodes at 25 W coagulation current
Study: 3429696
Drug: Long-acting propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting propranolol 60 mg (LA 60 mg)
Study: 3429696
Drug: Conventional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional propranolol 20 mg tid
Study: 30322091
Drug: Moringa oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa oleifera leaf powder (20 g)
Study: 1610589
Drug: 5-day preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day preoperative treatment with oral administration of 60 mg diltiazem 3 times daily, 10 mg diltiazem intravenously as a bolus dose before the beginning of the cardiopulmonary bypass, and 5 mg diltiazem intravenously 10 min before removal of aortic clamp
Study: 1610589
Drug: 5-day preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day preoperative treatment with oral administration of 60 mg diltiazem 3 times daily
Study: 1610589
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg diltiazem intravenously as a bolus dose before the beginning of CPB and 5 mg 10 min before removal of the aortic clamp
Study: 1610589
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg diltiazem in 1000 ml cardioplegic solution, given as additive
Study: 24750904
Drug: Standard stroke-unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard stroke-unit care without preventive antibiotic therapy
Study: 20124169
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation therapy (79.2 GyE)
Study: 11886356
Drug: IVMP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVMP 2 g/day
Study: 11886356
Drug: IVMP 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVMP 1 g/day
Study: 7843440
Drug: Subdermal levonorgestrel‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subdermal levonorgestrel‐releasing implant
Study: 1334803
Drug: Prinivil 10
Normalized name: Prinivil 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prinivil 10 to 40 mg once daily
Study: 1334803
Drug: Procardia XL
Normalized name: Procardia XL
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procardia XL 30 to 120 mg once daily
Study: 6502311
Drug: Bovine superoxide
Normalized name: Superoxide dismutase (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine superoxide dismutase (0.25 mg/kg)
Study: 9066005
Drug: ACEI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI treatment
Study: 18653268
Drug: ARB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB treatment
Study: 10543267
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg albendazole daily in three cycles of 6 weeks with 2 weeks between cycles
Study: 28524039
Drug: Gubiao Pixie
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gubiao Pixie prescription (Radix Astragali 30 g, Bran fried Rhizoma Atracylodis 20 g, Raidix Saposhnikoviae 12 g, Radix Scutellariae 10 g, Fructus Tsaoko 6 g), taken in warm water 300 mL, twice a day after meals for 10 days.
Study: 15307012
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy (indinavir + zidovudine or stavudine + lamivudine)
Study: 15307012
Drug: Dual-drug therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-drug therapy (zidovudine or stavudine + lamivudine)
Study: 7506324
Drug: Bimakalim (0.25-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimakalim (0.25-1 mg)
Study: 2366172
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with codeine
Study: 12891954
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous terbutaline infusion (SQ group)
Study: 12891954
Drug: Oral tocolytics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tocolytics (PO group)
Study: 8912763
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum albumin (< 30 mg/dl)
Study: 27701370
Drug: Intra-arterial administration
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial administration of iloprost (Endoprost®) after balloon angioplasty of below-the-knee vessels
Study: 26783035
Drug: Carbon nanoparticles
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon nanoparticles injection around the primary tumor
Study: 24599650
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection (control group)
Study: 30616675
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation (midazolam, propofol)
Study: 27847368
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated cholera vaccine CVD 103-HgR (Vaxchora)
Study: 21157384
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg · kg(‐1))
Study: 9562003
Drug: Pre‐to‐posttraining difference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐to‐posttraining difference in LVEF at peak dobutamine infusion
Study: 8148354
Drug: Linoleate-enriched diet
Normalized name: linoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linoleate-enriched diet with 1200 mg/d of alpha-tocopherol
Study: 8148354
Drug: Oleate-enriched diet
Normalized name: oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleate-enriched diet with 1200 mg/d of alpha-tocopherol
Study: 8148354
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet with 1200 mg/d of alpha-tocopherol
Study: 10866905
Drug: Fentanyl (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (dose per usual practice of the anesthesiologist)
Study: 2580180
Drug: Captopril and
Normalized name: captopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril and Hydrochlorothiazide (long-term treatment, 11 months)
Study: 22571225
Drug: Non-surgical debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical debridement without systemic antibiotics
Study: 20685496
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg/Paracetamol 500 mg
Study: 18394014
Drug: Low-dose HT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HT (1 mg of 17beta-estradiol and 0.5 mg of NETA)
Study: 3882657
Drug: Erythromycin stearate,
Normalized name: Erythromycin Stearate, stearate 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate, 1.5 g, administered orally 1 hour before extraction
Study: 11768839
Drug: Oral tolterodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tolterodine 2 mg BID (on days 1-14)
Study: 9244152
Drug: AM‐C10 (ampicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM‐C10 (ampicillin suppositories with sodium caprate)
Study: 9244152
Drug: AM (ampicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM (ampicillin suppositories without sodium caprate)
Study: 29973307
Drug: Incentive (intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive (intervention plus incentive; CAD $5.00 e‐gift card delivered weekly for completing action plans over 4 weeks)
Study: 8775589
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (encainide or flecainide)
Study: 1295821
Drug: GH regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH regimen of 25 IU/m2/week administered as a daily subcutaneous injection (16 short normal children, 9 males, 7 females)
Study: 31390305
Drug: Kinect-based educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinect-based educational games (Fruits) played once a week for 5 weeks in addition to standard treatment
Study: 28690041
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen (1 g IV)
Study: 28690041
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen (1 g oral)
Study: 28690041
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral placebo and volume-matched IV normal saline)
Study: 21484454
Drug: Photogem® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photogem® gel 50 mg/l (P50G)
Study: 21484454
Drug: Photogem® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photogem® gel 100 mg/l (P100G)
Study: 4014185
Drug: Interviewer-administered questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-administered questionnaire
Study: 25336165
Drug: Parenteral cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral cefazolin
Study: 25336165
Drug: Oral cefalexin
Normalized name: cephalexin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cefalexin
Study: 19615131
Drug: Xuebijing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing injection (100 ml twice a day for 7 days)
Study: 17524720
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (nitrogen and >or=10 kcal/kg/day of non‐protein calories for >or=5 days)
Study: 9521635
Drug: Isoflavonoids (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavonoids (55 mg daily, predominantly genistein)
Study: 28445783
Drug: Traditional SMA
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional SMA group focusing on medication management and self‐management counseling